Teva Buys Allergan Unit: How Mylan, Other Biotech Stocks Are Reacting

Loading...
Loading...
Shares of
Teva Pharmaceutical Industries Ltd (ADR)TEVA
surged to new 52-week highs of $69.05 Monday morning after the company announced its acquisition of
Allergan PLCAGN
's Generics segment for a total consideration of $40.5 billion. Shares of Allergan also spiked to new 52-week highs of $334.38 as the company will receive $33.75 billion in cash and $6.75 billion of Teva stock, representing under a 10 percent ownership stake of Teva. Israeli-based Teva stated in a
presentation that its acquisition is expected to achieve cost synergies and tax savings of $1.4 billion annually. The deal is also expected to be double digit non-GAAP earnings per share accretive in 2016 and more than 20 percent accretion in years two and three following the closing of the deal. The combined companies will combine for a pro-forma revenue of approximately $26.0 billion and PF EBITDA of around $9.5 billion in 2016. Accordingly, the new entity will become a top-10 global pharmaceutical company. The deal marks the largest in Israel's corporate history and prompted the pharmaceutical giant to drop its $40 billion hostile bid for Mylan NV MYL. Shares of Mylan plunged more than 12 percent Monday morning as some investors were anticipating a sale of the company to Teva at the proposed $82 per share offer. The hostile bid met resistance from Mylan's executive team who argued that a merger has no "industrial logic" or "cultural fit." According to a
report by Reuters,
Mylan said it will continue pursuing its acquisition of
Perrigo Company plc Ordinary SharesPRGO
. Investors reacted to the report as shares of Perrigo were trading higher by more than four percent.
Loading...
Loading...
Posted In: NewsAllerganAllergan Generic DrugsGeneric drugsisraelteva
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...